Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir + raltegravir
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simeprevir + raltegravir is a combination of two antiviral small molecule drugs, each with distinct mechanisms and indications. Simeprevir is an HCV NS3/4A protease inhibitor developed for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection, used in combination with peginterferon alfa and ribavirin. It inhibits the viral NS3/4A protease, blocking viral replication. Raltegravir is an HIV integrase inhibitor indicated for use in combination antiretroviral therapy to treat human immunodeficiency virus (HIV) infection; it works by inhibiting HIV integrase, preventing integration of viral DNA into the host genome[1][5][6][8]. Simeprevir was withdrawn from major markets due to newer agents with improved efficacy and safety profiles[2][3].
- Other names
- none
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on simeprevir + raltegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir + raltegravir.